| Literature DB >> 33005215 |
Ran Tian1,2, Xuan Zhang1,2, Si-Yao Li1, Qi-Ying Aixinjueluo1, Wai Ching Lam1, Zhao-Xiang Bian1,2.
Abstract
BACKGROUND: Moxibustion is one of the major interventions of Chinese medicine (CM). The systematic reviews (SRs) are essential references for evaluating the efficacy and safety of moxibustion interventions. This study aimed to assess the reporting quality of these SRs, particularly whether necessary information related to moxibustion was adequately reported.Entities:
Keywords: Chinese medicine; Meta-analysis; Moxibustion; PRISMA statement; Reporting quality; Systematic review
Year: 2020 PMID: 33005215 PMCID: PMC7526112 DOI: 10.1186/s13020-020-00385-z
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fourteen items for reporting assessment on Moxibustion-related information
| Items | Description |
|---|---|
| 1 | Whether a specific name of the moxibustion was reported in the “Title”? |
| 2 | Whether the CM syndrome(s) was included in the “Title”? |
| 3 | Whether the CM relevant theory was included in the “Introduction/Background” section? |
| 4 | Whether the CM diagnostic criteria of syndrome(s) were included in the “Eligibility criteria for participants”? |
| 5 | Whether CM-related outcomes (e.g., syndrome scores) were included in the “Eligibility criteria for outcome measures”? |
| 6 | Whether the environment information of moxibustion treatment was described? |
| 7 | Whether the materials and techniques used for moxibustion were reported? |
| 8 | Whether the types of moxibustion were reported? |
| 9 | Whether the selection of acupoints and meridians for moxibustion were reported? |
| 10 | Whether the number and frequency of the moxibustion sessions were reported? |
| 11 | Whether the duration of the moxibustion sessions was reported? |
| 12 | Whether any information about the adverse effects or safety assessment of the moxibustion were reported? |
| 13 | Whether the moxibustion characteristics were considered in the subgroup analysis, sensitivity analysis or other analysis of clinical heterogeneity in “Additional analyses” section? |
| 14 | Whether the heterogeneity of moxibustion interventions, such as types and dosage, has been fully considered when doing the data synthesis, especially about the meta-analysis? |
Fig. 1Flow chart of the performed search and selection process
Fig. 2The number of included moxibustion SRs from 2011 to 2019
General characteristics of included SRs
| Category | Descriptive characteristics | N (%) |
|---|---|---|
| Meta-analyses | Yes | 92 (94.8) |
| Number of authors included | 1–5 | 64 (66.0) |
| 6–10 | 31 (32.0) | |
| > 10 | 2 (2.1) | |
| Background of the first author | Clinician | 38 (39.2) |
| Researcher/methodologist | 59 (60.8) | |
| Institution of the first author | Hospital | 22 (22.7) |
| University | 73 (75.3) | |
| Research Institution | 2 (2.1) | |
| Types of primary studies included | RCTs | 97 (100) |
| Funding source | Yes | 55 (56.7) |
| Update of a previous review | Yes | 2 (2.1) |
Descriptive information of included SRs
| Category | Descriptive characteristics | N (%) |
|---|---|---|
| Types of moxibustion | Natural moxibustion | 11 (11.3) |
| Heat-sensitive moxibustion | 8 (8.2) | |
| Mild moxibustion | 8 (8.2) | |
| Indirect moxibustion | 3 (3.1) | |
| Not specifica | 67 (69.1) | |
| Classification of diseasesb | Diseases of the musculoskeletal system or connective tissue | 30 (30.9) |
| Diseases of the digestive system | 12 (12.4) | |
| Diseases of the respiratory system | 10 (10.3) | |
| Diseases of the nervous system | 9 (9.3) | |
| Diseases of the genitourinary system | 7 (7.2) | |
| Neoplasms | 5 (5.2) | |
| Certain infectious or parasitic diseases | 4 (4.1) | |
| Diseases of the circulatory system | 4(4.1) | |
| Pregnancy, childbirth or the puerperium | 4 (4.1) | |
| Sleep–wake disorders | 3 (3.1) | |
| Diseases of the immune system | 2 (2.1) | |
| Endocrine, nutritional or metabolic diseases | 2 (2.1) | |
| Mental, behavioural or neurodevelopmental disorders | 2 (2.1) | |
| Diseases of the visual system | 1 (1.0) | |
| Symptoms, signs or clinical findings, not elsewhere classified | 1 (1.0) | |
| Injury, poisoning or certain other consequences of external causes | 1 (1.0) |
aThe interventions were reported as moxibustion, either including all types of moxibustion interventions, or did not specify which types had been included
bAccording to International Statistical Classification of Diseases and Related Health Problems 11th Revision (ICD-11) Version
Reporting quality of 27 items of PRISMA (n = 97)
| Category | Item | Score, n (%) |
|---|---|---|
| Title | 1. Title | 83 (85.6) |
| Abstract | 2. Structured summary | 84 (86.6) |
| Introduction | 3. Rationale | 77 (79.4) |
| 4. Objective | 88 (90.7) | |
| Methods | 5. Protocol and registration | 12 (12.4) |
| Results | 6. Eligibility criteria | 92 (94.8) |
| 7. Information sources | 91 (93.8) | |
| 8. Search | 49 (50.5) | |
| 9. Study selection | 83 (85.6) | |
| 10. Data collection process | 83 (85.6) | |
| 11. Data items | 69 (71.1) | |
| 12. Risk of bias in individual studies | 83 (85.6) | |
| 13. Summary measures | 82 (84.5) | |
| 14. Synthesis of results | 83 (85.6) | |
| 15. Risk of bias across studies | 63 (64.9) | |
| 16. Additional analyses | 45 (46.4) | |
| 17. Study selection | 92 (94.8) | |
| 18. Study characteristics | 94 (96.9) | |
| 19. Risk of bias within studies | 76 (78.4) | |
| 20. Results of individual studies | 97 (100) | |
| 21. Synthesis of results | 69 (71.1) | |
| 22. Risk of bias across studies | 62 (63.9) | |
| 23. Additional analysis | 31 (32.0) | |
| Discussion | 24. Summary of evidence | 94 (96.9) |
| 25. Limitations | 73 (75.3) | |
| 26. Conclusions | 97 (100) | |
| Funding | 27. Funding | 55 (56.7) |
Reporting quality of 14 items of Moxibustion-related information (n = 97)
| Category | Item | Description | Yes, n (%) |
|---|---|---|---|
| Title | Title | 1. Reported the specific name of studied moxibustion | 25 (25.8) |
| 2. CM syndrome(s) was included | 0 (0) | ||
| Introduction | Rationale | 3. CM-related theory | 25 (25.8) |
| Methods | Eligibility criteria for participants | 4. Included CM syndrome diagnosis criteria | 6 (6.2) |
| Eligibility criteria for outcomes | 5. Included CM-related outcome(s) | 3 (3.1) | |
| Results | Study characteristics | 6. Reported treatment environment | 5 (5.2) |
| 7. Reported the materials and techniques used for moxibustion | 59 (60.8) | ||
| 8. Reported the types of moxibustion | 30 (30.9) | ||
| 9. Reported the selection of acupoints and meridians | 32 (33.0) | ||
| 10. Reported the number and frequency of the moxibustion | 27 (27.8) | ||
| 11. Reported the duration of the moxibustion | 42 (43.3) | ||
| 12. Reported the safety assessment or adverse effects (if exist) of the moxibustion | 30 (30.9) | ||
| Synthesis of results | 13. Considered moxibustion-specific characteristics in the subgroup analysis | 27 (27.8) | |
| 14. Meta-analyses were properly conducteda | 41 (44.6) |
aThe criteria of “properly conducted” was according to the homogeneity of the PICO information, especially the reporting quality of the details of moxibustion interventions and additional analyses provided as above. For example, if some of the moxibustion details were not reported, it is impossible to assess whether the meta-analyses in the SRs were properly conducted or not. In addition, of 97 included SRs, 92 had meta-analysis (as presented in Table 2). Thus, to calculate the proportion of this item, the percentage of records was based on the total number of 92. For example, 44.6% = 41/92